- Conditions
- Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
- Interventions
- ISM6331
- Drug
- Lead sponsor
- InSilico Medicine Hong Kong Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Chicago, Illinois • Cleveland, Ohio + 3 more
Location Directory
Clinical trials in Denver, Colorado
This page shows live ClinicalTrials.gov search results for Denver, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7459
Shown on this page
12
Current sort
Recently updated
Location scope
Denver, CO
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 745–756 of 7,459 matching trials in Denver, CO.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- COPD Acute Exacerbation
- Interventions
- Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
- Combination Product · Drug
- Lead sponsor
- Connect Biopharm LLC
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Palo Alto, California • Valencia, California + 17 more
- Conditions
- Anxiety
- Interventions
- Brief group neuroeducation
- Behavioral
- Lead sponsor
- Oregon State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Denver, Colorado
- Conditions
- Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
- Interventions
- Ipilimumab, Nivolumab, Patient Observation, Pembrolizumab
- Biological · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 482
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
- Interventions
- Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis, Nilotinib, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 291
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 209 more
- Conditions
- Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult, Hodgkin's Lymphoma, Relapsed, Adult
- Interventions
- MT-601
- Drug
- Lead sponsor
- Marker Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Duarte, California • Aurora, Colorado • Denver, Colorado + 4 more
- Conditions
- Dermatomyositis
- Interventions
- Brepocitinib, Placebo
- Drug
- Lead sponsor
- Priovant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 33 more
- Conditions
- KRAS P.G12C
- Interventions
- D3S-001, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Cetuximab
- Drug
- Lead sponsor
- D3 Bio (Wuxi) Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Orange, California • Palo Alto, California • Denver, Colorado + 4 more
- Conditions
- Skin Diseases, Bacterial
- Interventions
- Tigecycline, ampicillin-sulbactam
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • Jonesboro, Arkansas • Chula Vista, California + 27 more
- Conditions
- Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 507
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 345 more
- Conditions
- Non-muscle-invasive Bladder Cancer
- Interventions
- Gemcitabine, Docetaxel, Bacillus Calmette Guerin
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 229
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 163 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- Xaluritamig
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 12
- States / cities
- Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 7 more